Navidea biopharmaceuticals announces acceptance of abstract for presentation at the american college of rheumatology annual meeting

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the american college of rheumatology (“acr”) has accepted the results from the company’s second interim analysis of its ongoing nav3-31 phase 2b clinical study for presentation at the acr annual meeting (“acr convergence 2020”) under the title, “tc99m tilmanocept
NAVB Ratings Summary
NAVB Quant Ranking